Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register diphenidineSchedule I controlled substanceDEA schedulingcontrolled…
Policy Watch: 10 Regulatory Updates — April 01, 2026
Policy WatchApril 01, 2026. 10 regulatory items above the clinical relevance threshold of 40. Sources include Federal Register, regulations.gov, and regulatory RSS feeds. Listed in descending order of relevance score. Score 70Federal RegisterSchedules of…
Policy Watch: 10 Regulatory Updates — March 20, 2026
The DEA rescheduled marijuana from Schedule I to Schedule III, recognizing its medical utility. This regulatory update impacts prescribing restrictions for healthcare providers. The dea rescheduled marijuana change is a significant development in…
AM Policy Update: DEA Synthetic Opioids Schedule I Placement
The DEA synthetic opioids schedule I placement update on March 17, 2026, highlights key regulatory changes. This update covers multiple synthetic opioids classified under Schedule I. These changes impact controlled substance regulations and cannabis…